---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-344559"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2026-08-11T20:03:25+00:00"
generated_at: "2026-08-11T20:04:11.130967+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# enGene hosts Aug 11 virtual KOL event on NMIBC market research insights

## Summary
- Virtual KOL event held August 11, 2026 to discuss emerging non-muscle invasive bladder cancer (NMIBC) market research.
- Presentation filed as Exhibit 99.1; company positioned as non-viral genetic medicine developer.
- No clinical data, financial results, or guidance disclosed in the filing; exhibit contains only title and disclaimers.

## SEC filing metadata
- accession: 0001193125-26-344559
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2026-08-11T20:03:25+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312526344559/0001193125-26-344559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312526344559/engn-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-344559
- JSON: https://secwatch.observer/filing/0001193125-26-344559.json
- Plain text: https://secwatch.observer/filing/0001193125-26-344559.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.